Physician profile
Suzanne E Thompson
NPI 1003996273
$6,040.31
in general payments reported to CMS, 2019-2025
23 companies · $1,709 in 2025
The $1,709 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $360 · 2022: $922 · 2023: $1,211 · 2024: $1,839 · 2025: $1,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,758.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $881.26 | 2021-2025 | |
| Janssen Biotech, INC. | $491.41 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $447.17 | 2021-2025 | Entyvio, Eohilia, Gattex |
| E.R. Squibb & Sons, L.L.C. | $432.98 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $364.95 | 2024-2025 | Zenpep |
| Celgene Corporation | $358.25 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $330.19 | 2021-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $316.87 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $279.12 | 2023-2024 | Ocaliva |
| Genzyme Corporation | $278.42 | 2023-2025 | |
| Qol Medical, LLC | $278.03 | 2023-2024 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $257.20 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $236.27 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $219.17 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $209.61 | 2021-2024 | Linzess |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $143.80 | 2022-2023 | Rebyota |
| Lilly USA, LLC | $114.04 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $95.51 | 2022 | |
| Exact Sciences Corporation | $80.35 | 2024-2025 | Cologuard Collection Kit |
| Evoke Pharma, INC. | $80.10 | 2023-2025 | Gimoti |
| Intra-Sana Laboratories | $73.35 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Braintree Laboratories, INC. | $52.16 | 2022-2023 | Sutab |
| Novo Nordisk INC | $20.10 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.